HSA Extends Partnerships to Speed Access to Health Innovations Across Key Markets in Africa, Malaysia and Saudi Arabia

The Health Sciences Authority (HSA) is expanding regulatory reliance and cooperation across Africa, Malaysia and Saudi Arabia to reduce duplicated reviews, support faster access to safe and quality-assured health products, and strengthen Singapore’s role as a trusted regulatory gateway for biomedical innovation.

2            HSA announced these new and expanded collaborations between 14 and 16 September 2026 alongside the 30th International Medical Device Regulators Forum (IMDRF) and the Drug Information Association Singapore Annual Meeting 2026. They comprise new agreements with the African Medicines Agency and the Saudi Food and Drug Authority, Malaysia National Pharmaceutical Regulatory Agency’s pilot use of HSA’s medicine assessments, and deeper work with the United Kingdom’s Medicines and Healthcare products Regulatory Agency. Together, these initiatives aim to reduce duplicated regulatory work, improve the efficiency of health product evaluations across jurisdictions, and widen the opportunities for regulators in African countries, Malaysia and Saudi Arabia to reference HSA’s regulatory work. This will in turn support more timely access to safe and innovative products, and strengthen Singapore’s biomedical ecosystem and international regulatory leadership.

Furthering Regulatory Reliance on HSA approvals to Support Patient Access to Health Products

3            Memorandum of Understanding (MOU) with Saudi Food and Drug Authority (SFDA) - HSA signed an MOU with SFDA on 14 September 2026, Monday. The MOU aims to foster cooperation and facilitate the exchange of expertise, information and best practices on pre-market and post-market matters, technical sharing, and explore facilitative regulatory pathways for both conventional and novel products, including those involving biotechnology and artificial intelligence.